American Bio Medica

American Bio Medica EV/FCF

Delisted

The EV/FCF (Enterprise Value to Free Cash Flow) of American Bio Medica (ABMC) as of Nov 20, 2026 is -2.86. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -2.12 — a change of 34.76% (lower).

EV/FCF

-2.86

YoY

34.76%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of American Bio Medica is 2022 -2.86 . EV/FCF (Enterprise Value to Free Cash Flow) of American Bio Medica was 2021 -2.12 . It decreases by 34.76% lower compared to the previous year.

The American Bio Medica EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2015
7.90 USD
Jan 1, 2016
6.21 USD
Jan 1, 2017
10.85 USD
Jan 1, 2018
-5.85 USD
Jan 1, 2019
25.14 USD
Jan 1, 2020
-3.50 USD
Jan 1, 2021
-2.12 USD
Jan 1, 2022
-2.86 USD
The American Bio Medica EV/FCF history
YEAREV/FCFYoY
-2.86+34.76%
-2.12-39.43%
-3.50-113.94%
25.14-529.92%
-5.85-153.91%
10.85+74.56%
6.21-21.39%
7.90-90.02%
79.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Bio Medica Stock analysis

What does American Bio Medica do? American Bio Medica Corp is a US-based company specializing in the development and manufacture of drug testing devices and diagnostic products. The company was founded in 1986 and is headquartered in Kinderhook, New York. Its business model involves developing and producing drug testing devices and diagnostic products used by government agencies, companies, and private customers worldwide. The company also operates a laboratory that conducts diagnostic tests for third parties. Its five business areas include drug tests, medication safety, diagnostics, biometrics, and forensics. The company's products include urine, saliva, and sweat drug tests, as well as medical devices to prevent prescription drug abuse and diagnostic products for various diseases. It also offers biometric instruments and systems for person identification and forensic products for crime investigation. American Bio Medica Corp has been publicly traded since 1992 and has received several awards for its products and innovations. The company is committed to research and development, quality assurance, and accuracy in its products. Overall, it is a leading company in the field of drug testing devices and diagnostic products and is expected to continue to evolve in the future. American Bio Medica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Bio Medica stock

EV/FCF (Enterprise Value to Free Cash Flow) of American Bio Medica is -2.86 in 2022.

EV/FCF (Enterprise Value to Free Cash Flow) of American Bio Medica changed from -2.12 to -2.86, representing a 34.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) American Bio Medica since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s American Bio Medica with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — American Bio Medica

All Key Metrics — American Bio Medica